Just Classifying Emerging Compounds
In episode eleven of our Drugs Season, Just Science visits Atlanta for the 45th Annual ASCLD symposium to visit with Dr. Barry Logan, Sr. Vice President of Forensic Science Initiatives and Chief of Forensic Toxicology at National Medical Services, to discuss the convergence of drivers of the national opioid epidemic. Follow along to learn what’s in these novel compounds, and why it matters to illicit drug manufacturers, regulatory agencies, and local crime labs.
This episode of Just Science is funded by the National Institute of Justice’s Forensic Technology Center of Excellence [Award 2016-MU-BX-K110].
Dr. Barry K. Logan is Sr. Vice President of Forensic Science Initiatives, Chief Scientist, at NMS Labs in Willow Grove, Pennsylvania, where his responsibilities include management of toxicology resources, new test design and development, and expert testimony in forensic toxicology and chemistry. Dr. Logan is a Fellow of the American Board of Forensic Toxicologists (ABFT), and has over one hundred (100) publications and four hundred (400) presentations in forensic toxicology and analytical chemistry, including work on the effects of methamphetamine, cocaine and marijuana on drivers, drug caused and related death. His recent work has focused on the analytical and interpretive toxicology of emerging recreational and designer drugs. Dr. Logan’s other appointments include Executive Director of the Robert F. Borkenstein course at Indiana University, and Executive Director at the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation in suburban Philadelphia. He holds academic appointments at Indiana University, Arcadia University and Thomas Jefferson University. In recognition of his work and contributions, Dr. Logan has received numerous national and international awards, and in 2013-14 served as President of the American Academy of Forensic Sciences (AAFS).